Browse Studies — Arctuva

Phase 2

A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention…

Cognitive DysfunctionLewy Body DiseaseSynucleinopathies+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07589595

ObservationalRemote eligible

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and…

Parkinson DiseaseProdromal StageNeurodegenerative Diseases+8 more

Estimated

~$10 – $6,250

Radboud University Medical CenterNCT06993142

Natural History Study of Synucleinopathies

Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the …

Patients With SynucleinopathiesNeurogenic Orthostatic HypotensionPure Autonomic Failure+5 more

Estimated

~$10 – $1,125

NYU Langone HealthNCT01799915